| | 圳）有限 | | | 通 | | | --- | --- | --- | --- | --- | --- | | | 公司 | | | 过 核 | | | | | | | 查 | | | | 智驭医疗 | | | 整 改 | | | CQX2500066 | 科技（广 | 颅内血栓抽吸导管 | 珠海市香洲区唐家湾镇科技七路1号珠海中电高科技产业园4栋1-B单元（委托生产），珠 海市高新区唐家湾镇科创东路65号1栋4层（委托生产），珠海市唐家湾镇科技七路1号珠 | 后 通 | 2025/6/20 | | | 州）有限 公司 | | 海中电高科技产业园2栋203单元（委托生产） | 过 | | | | | | | 核 查 | | | | | | | 整 改 | | | | 深圳市辰 纳生物科 | 甲胎蛋白（AFP）测定 | | 后 | | | CSZ2500048 | 技有限公 | 试剂盒（化学发光法） | 深圳市南山区桃源街道塘长路2235号田寮工业A区9栋东座701、708、709 | 通 | 2025/6/23 | | | 司 | | | 过 核 | | | | | | | 查 | | | | | ...

广州万孚生物技术股份有限公司董事会 公司债权人如要求公司清偿债务或提供相应担保的，应根据《中华人民共和国公司法》等相关法律法规 的规定，向公司提出书面要求，并附随有关证明文件。如债权人未在规定期限内行使上述权利的，公司 本次回购注销限制性股票将按法定程序继续实施。 特此公告。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或者重大遗漏。 2025年7月4日，广州万孚生物技术股份有限公司（以下简称"公司"）召开2025年第一次临时股东大会， 审议通过了《关于终止实施 2024 年限制性股票激励计划暨回购注销限制性股票的议案》，因公司经营 所面临的内外部环境与制定股权激励计划时相比发生了较大变化，导致公司预期经营情况与激励方案考 核指标的设定存在偏差，继续推进和实施激励计划难以达到对激励对象的激励效果。经公司董事会审慎 考虑后，决定终止实施 2024 年限制性股票激励计划，并回购注销公司 2024 年限制性股票激励计划所涉 及的已授予但尚未解除限售的限制性股票 1054.40 万股，同时与之配套的《2024 年限制性股票激励计划 实施考核管理办法》等相关文件一并终止。具体内容详见公司 ...

广州万孚生物技术股份有限公司 关于回购注销部分限制性股票减少注册资本 暨通知债权人的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 2025 年 7 月 4 日，广州万孚生物技术股份有限公司（以下简称"公司"）召 开 2025 年第一次临时股东大会，审议通过了《关于终止实施 2024 年限制性股 票激励计划暨回购注销限制性股票的议案》，因公司经营所面临的内外部环境与 制定股权激励计划时相比发生了较大变化，导致公司预期经营情况与激励方案考 核指标的设定存在偏差，继续推进和实施激励计划难以达到对激励对象的激励效 果。经公司董事会审慎考虑后，决定终止实施 2024 年限制性股票激励计划，并 回购注销公司 2024 年限制性股票激励计划所涉及的已授予但尚未解除限售的 限制性股票 1054.40 万股，同时与之配套的《2024 年限制性股票激励计划实施 考核管理办法》等相关文件一并终止。具体内容详见公司于 2025 年 6 月 18 日披 露在巨潮咨询网（http://www.cninfo.com.cn）上的《关于终止实施 2024 年限制性 股票激励计划暨回购注销限 ...

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2025-034 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 2025 年第一次临时股东大会会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）2025 年第一次临时股 东大会于 2025 年 7 月 4 日 14:00 在公司 D 座三楼会议室召开。会议通知已于 2025 年 6 月 18 日在中国证监会指定的信息披露网站公告。本次股东大会由公 司董事会召集，董事长王继华女士主持，公司全体董事、监事、高级管理人 员、公司聘请的见证律师等相关人士出席、列席了本次会议。会议的召集、召 开与表决程序符合《公司法》和《公司章程》的规定。 股东出席情况：通过现场和网络投票的股东 301 人，代表股份 210,616,079 股，占公司有表决权股份总数的 43.7485％。其中： 特别提示： 1、本次股东大会无增加、变更、提案的情况。 2、本次股东大会以现场投票和网络投票相结合的 ...

北京市君合（广州）律师事务所 关于 广州万孚生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 二零二五年七月 | 北京总部 | 电话: (86-10) 8519-1300 | 上海分所 | 电话: (86-21) 5298-5488 | 广州分所 | 电话: (86-20) 2805-9088 | 深圳分所 | 电话: (86-755) 2939-5288 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 传真: (86-10) 8519-1350 | | 传真: (86-21) 5298-5492 | | 传真: (86-20) 2805-9099 | | 传真: (86-755) 2939-5289 | | 杭州分所 | 电话: (86-571) 2689-8188 | 成都分所 | 电话: (86-28) 6739-8000 | 西安分所 | 电话: (86-29) 8550-9666 | 青岛分所 | 电话: (86-532) 6869-5000 | | | 传真: (86-571) 2689-8199 | | 传真: ( ...

Core Viewpoint - The China Securities Social Development Security Industry Theme Index (CSI Security) has shown mixed performance, with a recent increase of 0.58% and a year-to-date rise of 0.39% [1]. Group 1: Index Performance - The CSI Security Index rose by 2.28% over the past month, but has decreased by 3.03% over the last three months [1]. - The index was established on June 29, 2012, with a base value of 1000.0 points [1]. Group 2: Index Composition - The top ten weighted stocks in the CSI Security Index include: - Huace Testing (9.28%) - Hikvision (7.9%) - Zhongke Shuguang (3.59%) - Wanfu Biology (2.94%) - Greenme (2.88%) - Meiya Optoelectronics (2.77%) - Southern Network Technology (2.48%) - Siwei Liekong (2.48%) - Dahua Technology (2.43%) - Aerospace Zhizhuang (2.4%) [1]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (67.13%) and the Shanghai Stock Exchange (32.87%) [1]. Group 3: Industry Breakdown - The industry composition of the index includes: - Industrial sector: 42.43% - Information technology: 41.81% - Public utilities: 5.46% - Communication services: 4.97% - Healthcare: 4.88% - Financial sector: 0.45% [2]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]. Group 5: Related Funds - Public funds tracking the CSI Security Index include Donghai CSI Social Development Security [3].

广州万孚生物技术股份有限公司 | 证券代码：300482 | 证券简称：万孚生物 公告编号：2025-033 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所可转换公司 债券业务实施细则》的有关规定，广州万孚生物技术股份有限公司（以下简称"公 司"）现将 2025 年第二季度可转换公司债券（以下简称"可转债"）转股及公司股 份变动的情况公告如下： 一、可转债发行上市概况 （一）可转债发行上市基本情况 经中国证券监督管理委员会"证监许可[2020]1830 号"文同意注册的批复，公 司于 2020 年 9 月 1 日向不特定对象发行了 600 万张可转换公司债券，每张面值 100 元，发行总额 6.00 亿元。 经深交所同意，公司 6.00 亿元可转换公司债券将于 2020 年 9 月 23 日起在 深交所挂牌交易，债券简称"万孚转债"，债券代码"123064"。 （二）可转债转股价格调整情况 根据《深圳证券交易所创业板股票上市规则》等规定和《广州万孚生物技术 股份有限公司向不特定对象发行可转换公司债券募集说明书》 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Guangzhou Wanfang Biological Technology Co., Ltd, particularly in the medical device industry [1][2] - As of June 24, the company's stock price closed at 21.06 yuan, with a rolling PE ratio of 19.04 times and a total market capitalization of 10.139 billion yuan [1] - The average PE ratio for the medical device industry is 49.12 times, with a median of 36.07 times, placing Wanfang Biological at the 45th position in the industry ranking [1] - The company reported a revenue of 800 million yuan for Q1 2025, reflecting a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross profit margin of 66.67% [2] Group 2 - As of March 31, 2025, the number of shareholders for Wanfang Biological increased to 42,296, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's main business includes the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1] - Wanfang Biological has received numerous accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national-level "green factory" in January 2025 [1]

Core Viewpoint - The credit rating agency has assigned a stable outlook to Guangzhou Wanfeng Biotechnology Co., Ltd. (Wanfeng Bio), reflecting its strong product line, significant R&D investment, and robust financial health despite facing industry challenges such as price pressures and increased competition [4][6][7]. Company Overview - Wanfeng Bio operates in the field of rapid diagnostic reagents and related instruments, with a diverse product line covering cardiovascular diseases, inflammation, tumors, infectious diseases, and drug abuse testing [4][16]. - The company has a global market presence, covering over 150 countries and regions, which helps mitigate operational risks [4][16]. Financial Performance - For the first quarter of 2025, Wanfeng Bio reported revenue of 800 million yuan, a year-on-year decrease of 7.06% [6]. - The company's total assets as of March 2025 were 7.183 billion yuan, with total liabilities of 596 million yuan, indicating a low debt level [5]. - The net profit for the same period was 190 million yuan, down from 565 million yuan in the previous year [5]. R&D and Product Development - Wanfeng Bio has increased its R&D investment, with 438.38 million yuan allocated in 2024, representing 14.30% of its revenue [16]. - The company launched 82 new products in 2024, including 75 reagent projects and 7 instruments, enhancing its product matrix [16]. Market Challenges - The industry is experiencing price pressures due to the normalization of centralized procurement and increased competition, particularly in the domestic market [6][12]. - The company faces uncertainties regarding the impact of tax changes on its reagent products, which shifted from simplified taxation to a general tax rate of 13% at the beginning of 2025 [6][12]. Future Outlook - Wanfeng Bio's credit rating outlook remains stable, supported by its diverse technology platforms and product lines, although it must navigate ongoing pricing pressures and competitive dynamics in the market [7][12]. - The company is expected to continue expanding its R&D efforts and product offerings to maintain its market position and drive future growth [4][16].

Group 1 - The core index, the China Securities Social Development Security Industry Theme Index, rose by 1.21% to 1596.77 points, with a trading volume of 34.7 billion yuan [1] - Over the past month, the index has decreased by 1.85%, down 11.26% over the last three months, and down 3.54% year-to-date [1] - The index includes no more than 100 securities from companies benefiting from social development security, covering sectors such as information security, environmental security, security equipment, and safety testing [1] Group 2 - The top ten holdings of the index are: Huace Testing (9.48%), Hikvision (8.05%), Zhongke Shuguang (3.6%), Wanfu Biology (2.93%), Meiya Optoelectronics (2.91%), Greeenmei (2.87%), Nanwang Technology (2.6%), Dahua Technology (2.43%), Aerospace Zhizhuang (2.35%), and Siwei Liekong (2.34%) [1] - The market share of the index's holdings is 67.16% from the Shenzhen Stock Exchange and 32.84% from the Shanghai Stock Exchange [1] Group 3 - The industry composition of the index's sample includes: 42.47% in industrials, 41.80% in information technology, 5.47% in utilities, 4.93% in communication services, 4.89% in healthcare, and 0.45% in finance [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December [2] Group 4 - Public funds tracking the index include Donghai China Securities Social Development Security [3]